1

2

3   A Molecular Signature for Anastasis, Recovery from the Brink of Apoptotic Cell Death

4

5

6

7

8   Gongping Sun, Elmer Guzman, Hongjun Robin Zhou,

9   Kenneth S. Kosik, and Denise J. Montell*

10

11

12

13   Molecular, Cellular, and Developmental Biology Department

14   Neuroscience Research Institute

15   University of California

16   Santa Barbara, CA 93106

17

18

19

20

21   *to whom correspondence should be addressed at denise.montell@lifesci.ucsb.edu

1

22   **Abstract**

23   **During apoptosis, executioner caspase activity has been considered a point of no**

24   **return. However, recent studies show that cells can survive caspase activation**

25   **following transient apoptotic stimuli, a process named anastasis. To identify a**

26   **molecular signature, we performed whole transcriptome RNA sequencing of**

27   **untreated, apoptotic, and recovering HeLa cells. We found that anastasis is an**

28   **active, two-stage program. During the early stage, cells transition from growth-**

29   **arrested to growing. In the late stage, cells change from proliferating to migratory.**

30   **Strikingly, some early recovery mRNAs were elevated first during apoptosis,**

31   **implying that dying cells poise to recover, even while still under apoptotic stress.**

32   **Furthermore, TGFβ-induced Snail expression is required for anastasis, and**

33   **recovering cells exhibit prolonged elevation of pro-angiogenic factors. This study**

34   **demonstrates similarities in the anastasis genes, pathways, and cell behaviors to**

35   **those activated in wound healing. This study identifies a repertoire of potential**

36   **targets for therapeutic manipulation of this process.**

37

Introduction

Apoptosis is a cell suicide program that is conserved in multicellular organisms and functions to remove excess or damaged cells during development and stress[1,2]. Excessive apoptosis contributes to degenerative diseases, whereas blocking apoptosis can cause cancer[3]. Apoptotic cells exhibit distinctive morphological changes[4] caused by activation of proteases called caspases[5,6]. Activation of executioner caspases is a necessary step during apoptosis[5] and until recently was considered a point of no return[7].

However executioner caspase activation is not always sufficient to kill cells under apoptotic stress. For example, caspase 3 activation in cells treated with sub-lethal doses of radiation or chemicals does not cause morphological changes or death, but rather allows cells to survive with caspase-dependent DNA damage that can result in oncogenic transformation[8–10]. In addition, transient treatment of cells with lethal doses of certain apoptosis inducers causes caspase 3 activation sufficient to cause apoptotic morphological changes, yet cells can survive after removing the toxin in a process called anastasis[11]. While most cells fully recover, a small fraction bear mutations, and an even smaller fraction undergo oncogenic transformation. Cell survival following executioner caspase activation has also been reported in cardiac myocytes responding to transient ischemia, in neurons over-expressing Tau, and during normal Drosophila development[12–15]. Taken together these studies suggest that cells can recover from the brink of apoptotic cell death and that this can salvage cells, limiting the permanent tissue damage that might otherwise be caused by a transient injury. However, the same process of anastasis in cancer cells might underlie recurrence following transient chemo- or radiation therapy.

61 Thus, defining the molecular changes occurring in cells undergoing this remarkable

62 recovery from the brink of death is a critical step toward manipulating this survival

63 mechanism for therapeutic benefit.

64

65 **Results**

66 **RNAseq reveals anastasis composes of two stages.**

67 To initiate apoptosis, we exposed HeLa cells to a 3 hr treatment with ethanol (EtOH),

68 which was sufficient to induce cell shrinkage and membrane blebbing (Figure 1A, B),

69 cleavage of PARP1, which is a target of caspase 3/7 (Figure 1I), and activation of a

70 fluorescent reporter of caspase 3 activity, in ~75% of the cells (Figure G, H, J,

71 supplementary video 1). Removal of the EtOH by washing allowed a striking recovery to

72 take place over the course of several hours, during which time ~70% of the cells re-

73 attached to the culture matrix and spread out again (Figure 1C-F, K, supplementary video

74 2)[11].

75

76 To define anastasis at a molecular level, we performed whole transcriptome RNA

77 sequencing (RNAseq) of untreated cells, apoptotic cells, and of cells allowed to recover

78 for 1, 2, 3, 4, 8, or 12 hours (Figure 1L). These time points include and extend beyond

79 the time needed for the major morphological changes, which appeared complete by 4

80 hours (Figure 1A-F). Compared to untreated cells, 900-1500 genes increased in

81 abundance >1.5-fold at each time point, while 250-750 genes decreased >1.5 fold (false

82 discovery rate <0.05) (Figure 1M, Supplementary table S1). Well-characterized genes

83 such as Fos, Jun, Klf4, and Snail were induced, as well as genes about which little is

84   known, such as the long non-coding RNA LOC284454, a gene predicted to encode a

85   deubiquitinating enzyme (OTUD1), a pseudokinase (TRIB1), and a phosphate carrier

86   protein (SLC34A3).

87

88   We validated the expression patterns of 27 top-ranked differentially expressed (22

89   upregulated and 5 downregulated) genes using quantitative reverse transcription PCR

90   (qRT-PCR). The results of RNAseq and qRT-PCR correlated well, with an R^2 of 0.89

91   (Figure 1N-P, Supplementary figure S1). Out of 22 top-ranked, up-regulated genes we

92   tested, 18 increased in abundance in HeLa cells recovering from apoptosis induced by a

93   second chemical (10% DMSO), and in a second cell line (human glioma H4 cells)

94   recovering from EtOH-induced apoptosis (Supplementary figure S2). This suggests that

95   there is a core anastasis response that is neither cell-line-specific nor apoptosis-inducer-

96   specific.

97

98   A principle component analysis (PCA) of the RNAseq data showed that cells undergoing

99   anastasis clustered into two distinct groups: one group composed of cells allowed to

100   recover for 1-4 hours, and a second containing cells that recovered for 8 or 12 hours.

101   Both groups were also clearly different from apoptotic cells and untreated cells (Figure

102   1Q). We therefore defined the first 4 hrs of recovery as the early stage, and 8 to 12 hrs as

103   late.

104

105   **Distinct features of early and late recovery**

106   To compare the transcriptional profiles between early and late stages, we used the

107   program AUTOSOME[16], which clusters genes according to similarities in their

108   expression patterns over time (Supplementary table S2). This approach identified 8

109   clusters containing a total of 1,172 genes upregulated during early recovery, and 6

110   clusters containing 759 genes upregulated late (Supplementary table S3). We refer to

111   these as early and late response genes, respectively (Figure 2A, Supplementary table S3).

112   Gene Ontology (GO) analysis revealed enrichment of expected categories such as

113   "regulation of cell death" and "cellular response to stress" in the early response (Figure

114   2B). The GO term "transcription" was the most significantly enriched, indicating

115   induction of transcription factors during initiation of anastasis (Figure 2B). The term

116   "chromatin modification" was also enriched. Enrichment of early response genes in

117   "regulation of cell proliferation" and "regulation of cell cycle" terms suggested that

118   removing apoptotic stress released cells from a growth-arrested state to re-enter the cell

119   cycle and proliferate (Figure 2B). Remarkably, the classes of early and late response

120   genes were very different. The late response was enriched in posttranscriptional activities

121   such as ncRNA processing and ribosome biogenesis.

122

123   KEGG pathway analysis showed early response genes to be enriched in cell cycle and

124   pro-survival pathways such as TGFβ, MAPK, and Wnt signaling (Figure 2C). The late

125   response showed enrichment in general post-transcriptional pathways such as ribosome

126   biogenesis, RNA transport, protein processing, and endocytosis, as well as specific

127   pathways such as focal adhesion and regulation of actin cytoskeleton (Figure 2C).

128

6

129 **Cells transition from proliferation to migration during recovery from apoptosis**

130 Consistent with enrichment of cell cycle and proliferation genes in the early response,

131 cell numbers increased during the first 11 hours of recovery (Figure 3A, Supplementary

132 figure S3), plateaued after 11 hours, and began to increase again at ~ 30 hours. At even

133 later time points (after replating), recovered cells exhibited a similar proliferation rate to

134 control, mock-treated cells (Figure 3B).

135

136 Due to the enrichment of "focal adhesion" and "regulation of actin cytoskeletion"

137 pathways in late response gene clusters (Figure 2C), we hypothesized that cells might

138 become migratory during the proliferation pause. To measure migration, we performed

139 wound-healing assays. Scratch wounds made in monolayers of cells allowed to recover

140 from EtOH treatment for 16 hrs closed faster than that in mock-treated monolayers

141 (Figure 3C, D), even though they exhibited a lower cell number and slightly slower

142 proliferation rate (Supplementary figure S4). In both mock-treated and EtOH-treated

143 cells, those that migrated to fill the wound were more elongated than cells lagging behind

144 (Figure 3E). A larger proportion of cells recovering from EtOH treatment showed this

145 elongated morphology compared to mock-treated cells (Figure 3F, G), suggesting this

146 morphology might facilitate migration and wound closure.

147

148 **Recovery from apoptotic stress is different from recovery from autophagy**

149 The observed enrichment of cell cycle components in the early response suggested that

150 one facet of anastasis is re-entry into the cell cycle following growth arrest during

151 apoptosis. To distinguish which molecular features of anastasis were common to another

7

152   type of growth arrest and recovery, and to identify those more likely to be specific to

153   anastasis, we evaluated the expression of the top-ranked, differentially expressed

154   anastasis genes in cells undergoing recovery from nutrient deprivation. Nutrient

155   deprivation induces growth arrest and autophagy, a process that can promote survival[17,18].

156   Autophagy results in degradation of cytoplasmic components in autophagosomes, which

157   are double-membrane-bound vesicles that sequester cytoplasm and fuse with

158   lysosomes[17]. However expression of autophagy genes was not induced during anastasis,

159   suggesting that the two survival mechanisms differ. A time course showed that amino

160   acid starvation for 2 hours induced autophagy in HeLa cells, shown by increased LC3

161   staining, which is a marker of for autophagosomes. LC3 staining is typically further

162   augmented by blocking fusion between autophagsomes and lysosomes with bafilomycin

163   A1[19], and this was also true in nutrient-deprived HeLa cells (Figure 4A-D). Two hours of

164   starvation did not induce caspase 3 activation (Figure 4E), although longer treatments

165   did. Of the 24 genes upregulated during anastasis that we tested, 10 were downregulated

166   or only slightly upregulated during recovery from autophagy (Figure 4F-O). Thus

167   elevated transcription of these 10 genes distinguishes cells in early anastasis from those

168   recovering from autophagy. Furthermore cells recovering from autophagy showed no

169   measurable difference in the rate of wound closure compared to mock treated cells

170   (Figure 4P, Q). Thus, cells recovering from transient apoptotic stress exhibit both

171   molecular and behavioral hallmarks that distinguish anastasis from recovery from other

172   types of stress that induce growth arrest.

173

174   **Cells poise for recovery during apoptosis.**

8

175 The transcriptional profile of cells undergoing anastasis revealed an unknown feature of

176 apoptotic cells that appears to contribute the rapid transition to recovery. We noticed that

177 transcripts corresponding to a subset of early response genes that were induced during the

178 first hour of anastasis were already elevated in abundance in apoptotic cells, relative to

179 untreated cells (Figure 1O, P, Figure 2A, Supplementary 1A-G). One possible

180 explanation would be that these are genes that drive apoptosis, and that apoptosis had not

181 completely stopped 1 hour after removal of the chemical stress. Alternatively, these could

182 be genes encoding proteins that contribute to recovery, and that cells prepare for that

183 possibility even after caspase activation. To distinguish between these opposing

184 possibilities, we compared the levels of expression of 10 such early genes at 1 hr of

185 recovery after 3 hr EtOH treatment, to the levels in cells left in EtOH for 4 hrs. The

186 mRNA levels after 4 hr EtOH treatment were significantly lower than those at 1 hr

187 recovery, indicating that accumulation of these mRNAs was associated with the survival

188 response (Figure 5A-J). We analyzed the corresponding protein levels for five of the

189 early response targets for which antibodies were available. The protein levels remained

190 unchanged or were slightly reduced during apoptosis (Figure 5K), suggesting that while

191 the mRNAs accumulated, their translation was inhibited, consistent with prior

192 observations of downregulated protein synthesis in apoptotic cells[20]. This intriguing

193 finding supports the idea that even during apoptosis, cells actually poise for recovery by

194 synthesizing, or protecting from degradation, specific mRNAs encoding survival

195 proteins, which are however not translated. If apoptotic stress persists, the mRNAs are

196 degraded and the cells die. However, if the apoptotic stress disappears, cells are prepared

9

197   to rapidly synthesize survival proteins. This 'poised for recovery' state may help to

198   explain the rapid recovery after stress removal.

199

200   **Knocking down Snail impaired recovery from apoptosis.**

201   Snail is one of the mRNAs enriched in apoptotic cells and then highly induced in early

202   recovery, and has been reported to protect cells from apoptosis[21,22]. We found that Snail

203   protein levels increased during recovery (Figure 5K). In addition, knocking down Snail

204   expression by stably expressing short hairpin RNA (shRNA) reduced the endogenous

205   Snail protein level (Figure 6A) and reduced the percentage of cells surviving EtOH-

206   induced apoptosis (Figure 6B). We also found increased PARP1 cleavage in Snail-

207   depleted cells following EtOH treatment (Figure 6A). Therefore the poor recovery

208   following Snail knockdown may result from enhanced caspase activation during EtOH

209   treatment, impaired anastasis, or both.

210

211   **Activation of TGFβ signaling contributes to Snail upregulation and migration.**

212   One important upstream regulator of Snail is TGFβ signaling[23], and this pathway was

213   enriched in the early recovery gene set. TGFβ signaling regulates transcription through

214   phosphorylation and activation of downstream transcription factors Smad2 and Smad3[24].

215   Phosphorylation of Smad2/3 increased during apoptosis and in the first hour of recovery,

216   then diminished after 4 hrs of recovery, indicating transient activation of TGFβ signaling

217   (Figure 6C). To test if Snail upregulation was due to TGFβ signaling, we treated cells

218   with a TGFβ receptor I specific inhibitor LY364947. LY364947 did not affect basal cell

10

219   survival or proliferation (Supplementary figure S5) but suppressed the induction of Snail

220   protein during recovery (Figure 6D).

221

222   TGFβ signaling activation can promote epithelial-to-mesenchymal transition (EMT) and

223   cell migration[25]. To determine if the transient activation of TGFβ signaling during early

224   recovery was responsible for the increased migration later, we inhibited TGFβ signaling

225   only during apoptosis and early recovery stage, then tested cell migration using the

226   wound-healing assay. Transient inhibition of TGFβ signaling by LY364947 reduced the

227   average migration speed of EtOH-treated cells from 45 to 37 μm/h while reducing the

228   average migration speed of mock-treated cells from 27 to 23 μm/h, suggesting TGFβ

229   signaling contributes to both basal motility and anastasis-induced migration in HeLa cells

230   (Figure 6E). Interestingly, TGFβ signaling, Snail mRNA, and Snail protein were all

231   downregulated during autophagy and recovery (Figure 4F, Figure 6C). Recovery from

232   autophagy did not stimulate cell migration (Fig 4P, Q), further supporting the idea that

233   activation of TGFβ signaling, induction of Snail, and increased migration characterize the

234   recovery from the brink of apoptotic cell death specifically, rather than general stress

235   responses.

236

237   **Induction of angiogenesis-related genes throughout recovery.**

238   While TGFβ signaling and Snail expression were transiently elevated during early

239   recovery, some angiogenesis-related genes were persistently elevated throughout the 12

240   hours examined. Placenta growth factor (PGF) binds vascular endothelial growth factor

241   receptor (VEGFR) and stimulates endothelial cell proliferation and migration[26]. PGF was

11

242   among the top 10 upregulated genes at every time point during apoptosis and recovery

243   (Supplementary table S1). PGF mRNA increased ~22-fold at 1hr recovery, and even after

244   24hr recovery, PGF mRNA was 3-fold higher in EtOH-treated cells compared to mock-

245   treated cells (Figure 7A, B).

246

247   Ephrin and Ephrin receptor (EphR) signaling are also important in blood vessel

248   development and angiogenesis [27,28]. Several EphRs (EPHA2, EPHB2, EPHB4) and

249   Ephrins (EFNB1, EFNB2) were upregulated throughout recovery (Supplementary table

250   S1). For example, expression of EFNB2 in the first hour of recovery was ~1.6 fold that of

251   mock-treated cells and elevated ~ 2-3 fold during 3-12 hours of recovery (Supplementary

252   figure S1K). EPHA2 was significantly upregulated after 24 hr recovery (Figure 7C).

253   Sprouty 2 (SPRY2) is a common transcriptional target of VEGFR and EphR signaling[29].

254   SPRY2 expression was upregulated from 4hr to 24hr recovery (Figure 7D-F), suggesting

255   activation of VEGFR and EphR signaling during recovery.

256

257   **Discussion**

258   The ability of cells to survive caspase-3 activity has implications for normal

259   development, cancer, and degenerative and ischemic diseases. Here we report the first

260   molecular characterization of cells recovering from the brink of apoptotic cell death. The

261   data show that anastasis proceeds in two clearly defined stages that are characterized by

262   distinct repertoires of genes. In the early stage, cells transcribe mRNAs encoding many

263   transcription factors and re-enter cell cycle. In the late stage, cells pause in proliferation

264   while increasing migration. While the proliferation and migration responses were

12

265   transient, others were longer lasting. For example, we found that cells that have

266   undergone anastasis elevate expression of angiogenesis-related genes for 24 hours. In

267   vivo, these factors would be expected to exert a non-autonomous effect of stimulating

268   blood vessel growth. Taken together the results presented here demonstrate that cells

269   recovering from the brink of apoptotic cell death express factors that promote

270   proliferation, survival, migration, and angiogenesis (Figure 8). The cell biological

271   processes involved in anastasis are thus reminiscent of wound healing responses [30],

272   consistent with the idea that cells evolved this capacity in order to limit permanent tissue

273   damage following a transient injury.

274

275   Many of the same molecular pathways are also upregulated during wound healing and in

276   cells undergoing anastasis including TGFβ, receptor tyrosine kinase, MAPK signaling,

277   and angiogenesis promoting pathways[30]. TGFβ signaling and Snail expression are

278   thought to promote EMT and chemotherapy resistance during tumor progression[31–33].

279   Cells undergoing anastasis activate TGFβ signaling and Snail expression, and become

280   migratory, all features of EMT. Two recent studies reported that EMT, though

281   dispensable for tumor metastasis, is required for tumor recurrence after

282   chemotherapy[34,35], suggesting that EMT is a survival strategy for tumor cells under stress

283   *in vivo*. Our results suggest a possible relationship between tumor recurrence, EMT, and

284   anastasis. If cancer cells exposed to radiation or chemotherapy during treatment escape

285   death via anastasis, TGFβ signaling and Snail expression would be induced, and these

286   critical regulators of EMT[32] would confer resistance to further chemotherapy and

287   radiation[33]. Therefore anastasis could in principle drive EMT-dependent tumor

288   recurrence.

289

290   In vivo, fast growing tumors require formation of new blood vessels to supply nutrients

291   and provide a route to metastasis[36]. Common cancer treatments, like tumor resection, can

292   induce extensive angiogenesis, which may promote tumor recurrence[37]. In fact, elevated

293   expression of angiogenic factors and/or increased blood vessel formation have been

294   found in recurrent craniopharyngioma, bladder cancer, squamous cell carcinoma after

295   surgery or irradiation[38–40]. Our results imply if tumor cells survive apoptosis triggered by

296   chemotherapy, irradiation or surgery, these survivors may upregulate production of pro-

297   angiogenic factors to facilitate angiogenesis and tumor recurrence.

298

299   In addition to providing insight into the molecular nature of anastasis, the work presented

300   here uncovers an unanticipated aspect of apoptosis. Even during apoptosis, cells poise for

301   recovery by accumulating mRNAs encoding survival proteins. The proteins however are

302   not expressed until and unless they are needed to reverse the apoptotic process. We

303   propose that this facilitates rapid recovery upon removal of the apoptotic stimulus.

304   Apoptosis and caspase 3 have been linked to tumor recurrence. In cancer patients, the rate

305   of recurrence is positively correlated with the amount of activated caspase 3 in tumor

306   tissues[41,42]. One explanation that has been offered to explain this somewhat paradoxical

307   result is that after radiotherapy or chemotherapy, activated caspase 3 promotes production

308   of pro-growth signals that are released from dying cells to stimulate proliferation of

309   living tumor cells, leading to tumor recurrence[41,43,44]. Dying cells can also secrete VEGF

14

310   in a caspase-dependent way to promote angiogenesis after irradiation[45]. These previous

311   studies proposed that apoptotic cells induce non-autonomous compensatory proliferation

312   in neighboring cells. The model is that cells that activate caspase 3 die and stimulate cells

313   without activated caspase to proliferate and grow. However, our study suggests another

314   possible mechanism underlying tumor recurrence: that tumor cells with activated caspase

315   3 themselves may eventually survive, proliferate, migrate, and trigger angiogenesis,

316   contributing to tumor repopulation.

317

318   When facing tissue injury, anastasis could in principle facilitate repair and regeneration,

319   and limit the permanent damage that might otherwise occur in response to a powerful but

320   temporary insult. On the other hand, anastasis would be detrimental if adopted by cancer

321   cells in response to chemo- or radiation therapy, thus potentially promoting recurrence.

322   Thus the mechanisms described here fit into the general idea that cancers mimic and co-

323   opt wound-healing behaviors[46]. Enhancing anastasis would be expected to be beneficial

324   in the context of degenerative or ischemic disease, whereas inhibiting anastasis should be

325   beneficial in cancer treatment.

326

327   **Materials and methods**

328   **Cell culture**

329   Human cervical cancer HeLa cells (ATCC cell line CCL-2), was grown in MEM

330   supplemented with GlutaMAX (Thermo Fisher Scientific), 10% fetal bovine serum

331   (Sigma), and 100U/ml Penicillin-Streptomycin (Thermo Fisher Scientific). Human

332   neuroglioma H4 cells (ATCC cell line HTB-148) were grown in high glucose DMEM

15

333   supplemented with GlutaMAX (Thermo Fisher Scientific), 10% fetal bovine serum, and

334   100U/ml Penicillin-Streptomycin. All cells were maintained at 37°C with 5% CO_2 and

335   90% humidity. Cells were tested for Mycoplasma contamination.

336

337   For RNAseq, 1.2×10^6 cells were seeded in each 100mm dish and cultured overnight. The

338   next day, cells were treated with either fresh growth medium or fresh growth medium

339   with 4.3% ethanol (EtOH) (Fisher Scientific) for 3 hrs. Samples from untreated and

340   apoptotic cells were collected at this moment. For recovery, medium was carefully

341   removed and fresh growth medium was added. For each time point, three biological

342   replicates were included.

343

344   For qRT-PCR, western blotting, and immunofluorescent antibody staining, 2×10^5 cells

345   were seeded in a 35mm dish or 6-well plate and cultured overnight. The next day, cells

346   were treated with either fresh growth medium, or fresh growth medium with 4.3%

347   (HeLa) or 4% (H4) EtOH for 3 hrs or fresh growth medium with 10% dimethyl sulfoxide

348   (DMSO) (Santa Cruz Biotechnologies) for 2.5 hrs, or Hanks' balanced salt solution

349   (HBSS) (Thermo Fisher Scientific) for 2 hrs. The precise concentration and time points

350   were chosen based on titration studies to achieve the highest possible percentage of

351   apoptotic cells that could recover. For recovery, medium was carefully removed and fresh

352   growth medium was added for the indicated period of time.

353

354   For TGFβ signaling inhibition, 5μM LY364947 (Sigma) was added to cells together with

355   mock or EtOH treatment.

16

356

RNA extraction

358 For RNA sequencing, total RNA was extracted using mirVana miRNA isolation kit

359 (Thermo Fisher Scientific) then treated with TURBO Dnase (Thermo Fisher Scientific) to

360 get rid of the genomic DNA. Ribosomal RNA (rRNA) was removed using RiboMinus

361 Eukaryote System v2 (Thermo Fisher Scientific). The quality of RNA was examined

362 using fragment analyzer (Advanced Analytical).

363

364 For qRT-PCR, RNA was extracted using RNeasy Mini kit (Qiagen) and treated with

365 TURBO DNase to remove genomic DNA.

366

RNA sequencing and data analysis

368 cDNA libraries used for sequencing were made from rRNA-depleted RNA using Ion

369 Total RNA-seq kit v2 (Thermo Fisher Scientific), and sequenced on an Ion Torrent

370 Proton sequencer (Thermo Fisher Scientific). Strand specific single-end reads were

371 generated from sequencing with average read lengths of 75 bp. Reads were mapped to

372 UCSC Human Reference Genome (hg19) using Tophat (v2.0.13)[47]. Reads covering gene

373 coding regions were counted using htseq (v0.6.1)[48] and resulting count data was used for

374 was used for downstream analysis. Count data were first filtered by removing genes with

375 low expression, or genes with less than 50 reads in more than 2 replicates per sample.

376 Remaining count data was normalized using trimmed mean of M-values method using

377 edgeR (v 3.14.0)[49]. Normalized count distributions were fit to a generalized linear model

378 in order to test for differential expression of genes (p-value=0.05) among multiple

379   samples. The differential expression test was corrected for multiple testing by applying

380   the Benjamini-Hochberg method on p-values to control false discovery rate.

381   AutoSOME[16] was used for identification of gene clusters with similar expression patterns

382   on CPM (counts per million) and log2 transformed count data.

383

384   Gene Ontology enrichment analysis was performed using DAVID

385   (https://david.ncifcrf.gov/) and PANTHER (http://pantherdb.org). Only the common GO

386   terms with Bonferroni P value less than 0.001 and FDR less than 0.001 were considered

387   significantly enriched. KEGG pathway enrichment analysis was performed using

388   WebGestalt (http://www.webgestalt.org).

389

390   **qRT-PCR**

391   RNA samples were reverse transcribed into cDNA using SuperScript III first-strand

392   synthesis system (Thermo Fisher Scientific). And qPCR was performed on QuantStudio

393   12K Flex real-time PCR system (Thermo Fisher Scientific) with Power SYBR green PCR

394   master mix. The primers used in qPCR are listed in supplementary table S4.

395

396   **Live imaging**

397   2×10^5 cells were seeded in each glass-bottom, 35mm dish (MatTek corporation). Cells

398   were incubated with Hoechst 33342 (Molecular Probes) for 20min, and imaged on Zeiss

399   LSM 780 with temperature and CO_2 control. Images were taken every 10min. Medium

400   change for EtOH treatment and recovery was carried out between scans. To monitor

18

401 caspase 3 activation during EtOH treatment lively, NucView 488 (Biotium) was added.

402 NucView488 binds irreversibly to DNA and thus inhibits anastasis.

403

404 **Western blotting**

405 Cells were lysed in laemmli sample buffer and run in 4-20% Mini-PROTEAN TGX

406 precast protein gels (Bio-rad). Primary antibodies used were rabbit anti-Egr1 (Cell

407 signaling #4154), rabbit anti-c-Fos (Cell signaling #2250), rabbit anti-c-Jun (Cell

408 signaling #9165), mouse anti-Snail (Cell signaling #3895), rabbit anti-PARP1 (Cell

409 signaling #9532), rabbit anti-Smad2/3 (Cell signaling #8685), rabbit anti-pSmad2/3 (Cell

410 signaling #8828), mouse anti-α-Tubulin (Sigma #T6199). Secondary antibodies used

411 were IRDye 800CW donkey anti-rabbit IgG (H+L), IRDye 680LT donkey anti-mouse

412 IgG (H+L), IRDye 800CW donkey anti-mouse IgG (H+L) (Li-Cor Biosciences). The

413 blots were scanned on Odyssey imaging system (Li-Cor Biosciences). Cell treatment,

414 sample collection and western blotting were repeated at least three times, and the

415 representative blots were shown in the figures.

416

417 **Immunofluorescent staining**

418 Cells were seeded in 6-well plate with coverslip. After treatment, cells were washed once

419 with PBS and fixed with cold methanol for 5min. Cells were then rinsed with PBS twice

420 and washed with PBS containing 0.2% Triton X-100 (Fisher Scientific). After that, cells

421 were blocked with PBS containing 0.2% Triton X-100 and 5% goat serum (Sigma). The

422 primary antibody and secondary antibody used are rabbit anti-LC3B (Cell signaling

423 #2775) and Alexa Fluor 488 conjugated goat anti-rabbit IgG (H+L) secondary antibody

19

424   (Thermo Fisher Scientific). The images were acquired on a Leica DMi8 microscope. Cell

425   treatment and staining were repeated three times, and the representative images were

426   shown in the figure.

427

428   **Short-hairpin RNA construct, transfection and stable cell line**

429   Short-hairpin RNA constructs were made in the pLVX vector. The sequences of snail

430   shRNA and scrambled shRNA were 5'-

431   GGATCTCCAGGCTCGAAAGtcaagagCTTTCGAGCCTGGAGATCCtttttt-3'[50] and 5'-

432   CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGtttttt-3'

433   (Addgene #1864). The constructs were transfected into HeLa cells using TurboFect

434   transfection reagent (Thermo Fisher Scientific), and selected using 2μg/ml puromycin

435   (Thermo Fisher Scientific) to get stable cell lines.

436

437   **Proliferation assay**

438   HeLa NucLight Red cells (Essen BioScience) were seeded in 6-well plate and cultured

439   overnight. After EtOH treatment, cells were cultured in growth medium and imaged in

440   the IncuCyte Zoom (Essen BioScience) every hour. 9 fields of view were taken per well,

441   and the number of red fluorescent nuclei was counted using IncuCyte Zoom software

442   (Essen BioScience).

443

444   **Wound healing assay**

445   HeLa NucLight Red cells were seeded in 100mm dish and cultured overnight. After

446   treatment and 16hr recovery, cells were trypsinized and seeded in Matrigel-coated 96-

20

447   well ImageLock plate (Essen BioScience) at 4×10^4 cells per well. After 4hrs, wound was

448   made in each well using WoundMaker (Essen BioScience). The wound closure process

449   was imaged in IncuCyte Zoom every hour.

450

Recovery rate quantification

451

452   Before treatment, cells seeded in 6-well plate were incubated with growth medium with

453   DRAQ5 (Thermo Fisher Scientific) for 10min at 37C, and imaged in IncuCyte Zoom to

454   quantify the original cell number. After 4hr recovery, cells were washed twice with PBS

455   to remove floating dead cells, and stained with DRAQ5 again. The cell number was

456   quantified again as the number of survivors. The recovery rate was calculated as the ratio

457   between the number of survivors to the original cell number.

458

Statistical analyses

459

460   Statistical analysis used in RNAseq data analysis was described in the "RNA sequencing

461   and data analysis" section. For other experiments, statistical significance was determined

462   using unpaired, two-tailed, t-tests with Welch's correction for comparison between two

463   samples, and one-way ANOVA to compare more than two samples, with $P < 0.05$ set as

464   criteria for significance. The Tukey test was used to derive adjusted P value for pairwise

465   comparison among multiple samples. Sample size was not predetermined.

466

Data availability

467

468   The RNAseq data have been deposited in the Gene Expression Omnibus (GEO) under

469   accession ID GSE86480.

470

21

474

475   **Author contributions:** E. G. participated in preparing libraries for RNAseq and carried

476   out bioinformatics analyses of the data. H. R. Z. carried out the mapping of RNAseq

477   reads. K. K. provided advice on the design, execution, and interpretation of the RNAseq

478   data. G. S. carried out the majority of experiments presented and participated in preparing

479   libraries for RNAseq and in the bioinformatics analysis. G. S. also prepared the figures

480   and wrote the first draft of the manuscript. D.J.M. conceived of and coordinated the

481   study, advised G. S. in all aspects of the work, contributed to design and interpretation of

482   the results, and revised the manuscript.

483

484   **Conflict of interest:** The authors declare no conflict of interest.

Reference

1   Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol* 2007; **35**: 495–516.

2   Fuchs Y, Steller H. Programmed cell death in animal development and disease. *Cell* 2011; **147**: 742–758.

3   Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of apoptosis in disease. *Aging* 2012; **4**: 330–349.

4   Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972; **26**: 239–257.

5   Kumar S. Caspase function in programmed cell death. *Cell Death Differ* 2007; **14**: 32–43.

6   Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? *Cell* 1995; **82**: 349–352.

7   Green D, Kroemer G. The central executioners of apoptosis: caspases or mitochondria? *Trends Cell Biol* 1998; **8**: 267–271.

8   Liu X, He Y, Li F, Huang Q, Kato TA, Hall RP *et al.* Caspase-3 promotes genetic instability and carcinogenesis. *Mol Cell* 2015; **58**: 284–296.

9   Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, Delgado ME *et al.* Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. *Mol Cell* 2015; **57**: 860–872.

10   Lovric MM, Hawkins CJ. TRAIL treatment provokes mutations in surviving cells. *Oncogene* 2010; **29**: 5048–5060.

11   Tang HL, Tang HM, Mak KH, Hu S, Wang SS, Wong KM *et al.* Cell survival, DNA

23

508 damage, and oncogenic transformation after a transient and reversible

509 apoptotic response. *Mol Biol Cell* 2012; **23**: 2240–2252.

510 12 Ding AX, Sun G, Argaw YG, Wong JO, Easwaran S, Montell DJ. CasExpress reveals

511 widespread and diverse patterns of cell survival of caspase-3 activation during

512 development in vivo. *elife* 2016; **5**. doi:10.7554/eLife.10936.

513 13 de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL *et al.*

514 Caspase activation precedes and leads to tangles. *Nature* 2010; **464**: 1201–

515 1204.

516 14 Levayer R, Dupont C, Moreno E. Tissue Crowding Induces Caspase-Dependent

517 Competition for Space. *Curr Biol* 2016; **26**: 670–677.

518 15 Kenis H, Zandbergen HR, Hofstra L, Petrov AD, Dumont EA, Blankenberg FD *et*

519 *al.* Annexin A5 uptake in ischemic myocardium: demonstration of reversible

520 phosphatidylserine externalization and feasibility of radionuclide imaging. *J*

521 *Nucl Med* 2010; **51**: 259–267.

522 16 Newman AM, Cooper JB. AutoSOME: a clustering method for identifying gene

523 expression modules without prior knowledge of cluster number. *BMC*

524 *Bioinformatics* 2010; **11**: 117.

525 17 Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the

526 interplay of autophagy and apoptosis. *Nat Rev Mol Cell Biol* 2014; **15**: 81–94.

527 18 Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between

528 apoptosis, necrosis and autophagy. *Biochim Biophys Acta* 2013; **1833**: 3448–

529 3459.

530 19 Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy

531   research. *Cell* 2010; **140**: 313–326.

532   20 Liwak U, Faye MD, Holcik M. Translation control in apoptosis. *Exp Oncol* 2012;

533   **34**: 218–230.

534   21 Franco DL, Mainez J, Vega S, Sancho P, Murillo MM, de Frutos CA *et al.* Snail1

535   suppresses TGF-beta-induced apoptosis and is sufficient to trigger EMT in

536   hepatocytes. *J Cell Sci* 2010; **123**: 3467–3477.

537   22 Wan Z, Pan H, Liu S, Zhu J, Qi W, Fu K *et al.* Downregulation of SNAIL sensitizes

538   hepatocellular carcinoma cells to TRAIL-induced apoptosis by regulating the

539   NF-κB pathway. *Oncol Rep* 2015; **33**: 1560–1566.

540   23 Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces

541   snail transcription factor in epithelial cell lines: mechanisms for epithelial

542   mesenchymal transitions. *J Biol Chem* 2003; **278**: 21113–21123.

543   24 Massagué J. TGF-beta signal transduction. *Annu Rev Biochem* 1998; **67**: 753–

544   791.

545   25 Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal

546   transition. *Cell Res* 2009; **19**: 156–172.

547   26 De Falco S. The discovery of placenta growth factor and its biological activity.

548   *Exp Mol Med* 2012; **44**: 1–9.

549   27 Salvucci O, Tosato G. Essential roles of EphB receptors and EphrinB ligands in

550   endothelial cell function and angiogenesis. *Adv Cancer Res* 2012; **114**: 21–57.

551   28 Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities.

552   *Annu Rev Pharmacol Toxicol* 2015; **55**: 465–487.

553   29 Cabrita MA, Christofori G. Sprouty proteins, masterminds of receptor tyrosine

554 kinase signaling. *Angiogenesis* 2008; **11**: 53–62.

555 30 Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and

556 regeneration. *Nature* 2008; **453**: 314–321.

557 31 Brunen D, Willems SM, Kellner U, Midgley R, Simon I, Bernards R. TGF-β: an

558 emerging player in drug resistance. *Cell Cycle* 2013; **12**: 2960–2968.

559 32 Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin*

560 *Invest* 2009; **119**: 1420–1428.

561 33 Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY *et*

562 *al.* Snail and slug mediate radioresistance and chemoresistance by antagonizing

563 p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer

564 cells. *Stem Cells* 2009; **27**: 2059–2068.

565 34 Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H *et al.* Epithelial-to-

566 mesenchymal transition is dispensable for metastasis but induces

567 chemoresistance in pancreatic cancer. *Nature* 2015; **527**: 525–530.

568 35 Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC *et al.* Epithelial-to-

569 mesenchymal transition is not required for lung metastasis but contributes to

570 chemoresistance. *Nature* 2015; **527**: 472–476.

571 36 Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. *Vasc*

572 *Health Risk Manag* 2006; **2**: 213–219.

573 37 Kong B, Michalski CW, Friess H, Kleeff J. Surgical procedure as an inducer of

574 tumor angiogenesis. *Exp Oncol* 2010; **32**: 186–189.

575 38 Sun HI, Akgun E, Bicer A, Ozkan A, Bozkurt SU, Kurtkaya O *et al.* Expression of

576 angiogenic factors in craniopharyngiomas: implications for tumor recurrence.

577   *Neurosurgery* 2010; **66**: 744–50; discussion 750.

578 39   Dinh TV, Hannigan EV, Smith ER, Hove MJ, Chopra V, To T. Tumor angiogenesis

579   as a predictor of recurrence in stage Ib squamous cell carcinoma of the cervix.

580   *Obstet Gynecol* 1996; **87**: 751–754.

581 40   Agrawal U, Mishra AK, Salgia P, Verma S, Mohanty NK, Saxena S. Role of tumor

582   suppressor and angiogenesis markers in prediction of recurrence of non muscle

583   invasive bladder cancer. *Pathol Oncol Res* 2011; **17**: 91–101.

584 41   Huang Q, Li F, Liu X, Li W, Shi W, Liu F-F *et al.* Caspase 3-mediated stimulation of

585   tumor cell repopulation during cancer radiotherapy. *Nat Med* 2011; **17**: 860–

586   866.

587 42   Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H *et al.* Low levels of

588   Caspase-3 predict favourable response to 5FU-based chemotherapy in

589   advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach. *Cell*

590   *Death Dis* 2016; **7**: e2087.

591 43   Donato AL, Huang Q, Liu X, Li F, Zimmerman MA, Li C-Y. Caspase 3 promotes

592   surviving melanoma tumor cell growth after cytotoxic therapy. *J Invest Dermatol*

593   2014; **134**: 1686–1692.

594 44   Cheng J, Tian L, Ma J, Gong Y, Zhang Z, Chen Z *et al.* Dying tumor cells stimulate

595   proliferation of living tumor cells via caspase-dependent protein kinase Cδ

596   activation in pancreatic ductal adenocarcinoma. *Mol Oncol* 2015; **9**: 105–114.

597 45   Feng X, Tian L, Zhang Z, Yu Y, Cheng J, Gong Y *et al.* Caspase 3 in dying tumor

598   cells mediates post-irradiation angiogenesis. *Oncotarget* 2015; **6**: 32353–32367.

599 46   Dvorak HF. Tumors: wounds that do not heal-redux. *Cancer Immunol Res* 2015;

600   **3**: 1–11.

601   47   Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ *et al.*

602   Transcript assembly and quantification by RNA-Seq reveals unannotated

603   transcripts and isoform switching during cell differentiation. *Nat Biotechnol*

604   2010; **28**: 511–515.

605   48   Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-

606   throughput sequencing data. *Bioinformatics* 2015; **31**: 166–169.

607   49   Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for

608   differential expression analysis of digital gene expression data. *Bioinformatics*

609   2010; **26**: 139–140.

610   50   Lee SY, Jeon HM, Ju MK, Kim CH, Yoon G, Han SI *et al.* Wnt/Snail signaling

611   regulates cytochrome C oxidase and glucose metabolism. *Cancer Res* 2012; **72**:

612   3607–3617.

613

614

615 **Figure 1. RNAseq defines anastasis as a two-stage active process.**

616 A-F) Time-lapse live imaging of HeLa cells before EtOH treatment (A), after 3hr EtOH

617 treatment (B), and after recovery for 1hr (C), 2hrs (D), 3hrs (E), and 4hrs (F). G-H)

618 Caspase 3 activity (green fluorescence) in the same group of cells before (G) and after

619 (H) 3hr EtOH treatment. DAPI staining is shown in blue in A-H. Scale bar is 50μm. I)

620 Western blots of full-length PARP1 (FL-PARP1) and cleaved PARP1 in cells after 3hrs

621 mock or EtOH treatment (T) followed by 21hrs recovery (R). J) Quantification of the

622 percentage of cells with active caspase 3 during EtOH treatment (n=5). K) The ratio of

623 the number of remaining cells right after washing away EtOH (R0h) or after 5hr recovery

624 (R5h) to the number of cells after mock treatment (n=3). L) The workflow of RNAseq

625 experiments. M) Numbers of upregulated and downregulated genes in apoptotic cells,

626 cells after 1hr, 2hr, 3hr, 4hr, 8hr, and 12hr recovery compared to untreated cells (fold

627 change>1.5, false discovery rate < 0.05). N) Correlation of RNAseq and qRT-PCR data

628 for 27 genes. O, P) Comparison of the changes in levels of FOS (O) and SNAI1 (P)

629 mRNAs over time detected by RNAseq and qRT-PCR. In n-p, 'fold change' is compared

630 to the expression level in untreated cells. Q) Principal component analysis of RNAseq

631 data reveals four clusters: untreated cells, apoptotic cells, 1-4 hrs recovery, and 8 and 12

632 hrs recovery. Each color represents a different time point. Each time point was analyzed

633 in triplicate.

634

29

635 **Figure 2. AUTOSOME and enrichment analyses of early and late response genes.**

636 A) AUTOSOME analysis. The red indicates increases and blue indicates decreases in

637 mRNA abundance. Genes most highly upregulated during 1 to 4hrs recovery are defined

638 as early response genes, and those that peak at 8 or 12hrs are late response genes. Red

639 bracket points out the genes upregulated in both apoptosis and early recovery. B) GO

640 enrichment analysis of early response genes and late response genes. C) KEGG pathway

641 enrichment analysis of early and late response genes. In B and C), P value is the

642 Bonferroni P value.

643

644 **Figure 3. Cells transition from proliferation to migration during recovery.**

645 A) Cell number during recovery after mock or EtOH treatment (n=3). B) Cells after 47hr

646 recovery from mock or EtOH treatment were trypsinized and re-plated at similar density.

647 The curves show the change of cell number over 22hrs (n=3). C, D) wound healing

648 assays. C) Quantification of wound width over time (n=8). The stars above each time

649 point present the statistical significance of the difference between cells after mock versus

650 EtOH treatment. *: P<0.05. **: P<0.01. ***: P<0.001. ****: P<0.0001. D) Images of

651 wounds made in cells recovering from mock treatment (D' and D'') or EtOH treatment

652 (D''' and D''''). The yellow lines mark the wound margins. E) Magnified images of the

653 outlined regions in (D''''). F and G) Images of confluent monolayers of cells recover

654 from mock (F) or EtOH (G) treatment. In E and G, yellow arrows point to elongated

655 cells. In all plots, error bars represent standard error of mean.

656

657 **Figure 4. Comparison between anastasis and recovery from autophagy**

658 A-D) LC3B autophagosome marker staining (green) in cells incubated with growth

659 medium containing 1% DMSO (control) (A), or HBSS containing 1% DMSO (B), or

660 growth medium containing 100nM Bafilomycin A1 (C), or HBSS containing

661 Bafilomycin A1 (D). E) Western blot for PARP1 showing little cleavage during amino

662 acid starvation. The 2hr time point was chosen for further studies. F-O) Comparison

663 between the mRNA levels of indicated genes after 0hr, 1hr, and 4hr recovery from

664 apoptosis (gray bars) or from autophagy (black bars). 'fold change' is compared to

665 expression level of mock-treated cells. *: $P<0.05$. **: $P<0.01$. ***: $P<0.001$. ****:

666 $P<0.0001$. n=3. P) Relative wound width over time in wound healing assay (n=5). Q)

667 Images of wounds made in cells recovering from mock treatment (upper two panels) or

668 amino acid starvation (lower two panels). Yellow lines mark the margin of wound. In all

669 bar graphs, error bars represent standard error of mean.

670   **Figure 5. Apoptotic cells were poised for recovery.**

671   A-J) mRNA levels of the indicated genes relative to mock-treated cells after 3hr mock

672   treatment (mock-T3R0), after 3hr EtOH treatment (EtOH-T3R0), after 1hr recovery from

673   EtOH treatment (EtOH-T3R1) and after 4hr EtOH treatment (EtOH-T4R0) (n=3). Stars

674   show statistic significance between EtOH-T3R1 and EtOH-T4R0. *: $P<0.05$. **: $P<0.01$.

675   ***: $P<0.001$. ****: $P<0.0001$. K) The protein levels of Egr1, c-Fos, c-Jun, Snail during

676   recovery from mock treatment and EtOH treatment.

677

678 **Figure 6. Transient activation of TGFβ signaling induced Snail upregulation, which**

679 **was required for anastasis, and caused increased migration in late stage.**

680 A) Cleavage of PARP1 and Snail protein in HeLa cells stably expressing scrambled

681 shRNA (scr shRNA) or snail shRNA treated with or without EtOH for 3hrs. B) Recovery

682 rate of untransfected HeLa, HeLa-scr shRNA, and HeLa-snail shRNA cells after mock

683 treatment or EtOH treatment (n=3). In all bar graphs, error bars represent standard error

684 of mean. C) Western blots of phosphor-Smad2/3, total Smad2/3, Snail in cells recovering

685 from mock treatment, EtOH treatment or starvation. D) The level of pSmad2/3, Smad2/3

686 and Snail in apoptotic cells (T3R0), cells after 1hr recovery (T3R1) and 4hr recovery

687 (T3R4). The addition of LY364497 and EtOH is indicated. E) Average migration speed

688 of the indicated group of cells during wound healing assay (n=8). Before wound healing

689 assay cells were treated with or without EtOH together with 0.1% DMSO or 5μM

690 LY364947 for 3 hrs, followed by 4 hrs recovery with 0.1% DMSO or 5μM LY364947

691 and an additional 16 hrs recovery without any inhibitor. Error bars represent 95%

692 confidence interval. *: P<0.05. **: P<0.01. ***: P<0.001. ****: P<0.0001.

693

34

694   **Figure 7. Angiogenesis-related genes were persistently upregulated during recovery.**

695   mRNA expression of PGF (A, B), EPHA2 (C), SPRY2 (D-F) in cells recover from mock

696   or EtOH treatment for the indicated time (R). Error bars represent standard error of mean.

697   *: P<0.05. **: P<0.01. ***: P<0.001. ****: P<0.0001.

698

699   **Figure 8. Schematic of events in anastasis.**

700   During apoptosis, cells poise for recovery. If the stress persists, cells die. If the stress is

701   removed, cells undergo two stages of recovery.

Figure 1

# Figure 2

Figure 3

A — after mock treatment / after EtOH treatment

B — after 47h recovery from mock treatment / after 47h recovery from EtOH treatment

C — after mock treatment / after EtOH treatment

D — recover from mock treatment (D', D''); recover from EtOH treatment (D''', D''''); migrate 0h / migrate 13h

E, F, G

Figure 4

Figure 5

Figure 6

A

B

C

D

E

Figure 7

Figure 8